Bariatric Embolization of Arteries With Imaging Visible Embolics (BEATLES) (BAE2)
Bariatric Embolization of Arteries With Imaging Visible Embolics
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female, aged ≥21 and ≤70 years
- Willing, able, and mentally competent to provide written informed consent
- Obese patients with a BMI ≥35 kg/m2
- Weight ≤400 lb
- Vascular anatomy (including celiac, hepatic, and gastric arteries) that in the opinion of the interventional radiologist is amendable to bariatric embolization, as assessed via 3D CT angiography
- Suitable for protocol therapy, as determined by the interventional radiology investigator
- Adequate hematologic (neutrophils>1.5x109/L, platelets>70x109/L, international normalized ratio (INR<1.5), hepatic (bilirubin≤2.0mg/dL, albumin≥2.5g/L), and renal (estimated glomerular filtration rate (GFR)>60milliliter mL/min. 1.73m2) function
- For females of reproductive potential: agreement to use of highly effective contraception
- for duration of study participation
- Patients who have failed conservative weight loss therapies such as supervised low calorie diets combined with behavior therapy and exercise
- Live or work within 65 miles of the enrolling institution in case a catastrophic post embolization event occurs
Exclusion Criteria:
- hemoglobin A1c greater than 8%
- Patients who are currently taking either Insulin or sulfonylurea (medication changes are allowed)
- Prior history of gastric, pancreatic, hepatic, and/or splenic surgery
- Prior radiation therapy to the upper abdomen
- Prior embolization to the stomach, spleen, or liver
- Cirrhosis
- Known portal venous hypertension
- Active peptic ulcer disease
- Significant risk factors for peptic ulcer disease, including daily NSAID use
- Large hiatal hernia, defined as >5 cm in size
- Active H. Pylori infection
- Known aortic pathology, such as aneurysm or dissection
- Renal insufficiency, as evidenced by an estimated glomerular filtration rate of <60 milliliter(mL)/min
- Major comorbidity, such as active cancer, significant cardiovascular disease, or peripheral arterial disease
- Pregnancy
- Pre-existing chronic abdominal pain
- Positive stool occult blood study
- GI bleeding or bleeding diathesis within 5 years
- Weight loss (intentional or unintentional) of more than or equal to 5% of body weight in the 6 months prior to randomization
- A weight loss greater than 6lb during the weight management run- in
- Use of anti-obesity medications in the 12 months prior to screening
- Endoscopic findings that would preclude bariatric embolization (at the discretion of the study team)
- History of gastric motility disorders or an abnormal nuclear gastric motility examination (to be performed in diabetic subjects only)
- American Society of Anesthesiologists Class 4 or 5 (very high risk surgical candidates: class 4=incapacitating disease that is a constant threat to life) at the time of screening for enrollment into the study - this exclusion criterion exists, because of the possibility that surgical intervention will be needed if the study intervention subsequently leads to severe adverse effects
- Inflammatory bowel disease
- Autoimmune disease or HIV+
- History of allergy to iodinated contrast media
- Failure to comply with pre-procedure weight management "run-in", or other pre-procedural visits (specifically, participants must complete 80% of weight management and Lose It! Food tracking, and 100% of one-time visits, i.e. MRI, computed tomography angiography (CTA), endoscopy)
- Applicability of any contraindication regarding patient's vasculature as per Instruction for Use
- Inability to have an MRI scan (i.e., metal implants or claustrophobia)
- Smokers/vape users/tobacco use
- Active or new-onset endocrine disorders (stable disease acceptable)
- Other unforeseen conditions that may make patients unsuitable for the procedure (study team discretion)
Exclusion Criteria (Psychiatric):
- As determined by clinical judgment based on Clinical Interview, psychological/behavioral measures, medical records, previous mental health records/other collateral information (as available) and consistent with diagnostic and statistical manual of mental disorders (DSM) -5 criteria:
- Diagnosis of severe mental illness (i.e., chronic psychotic spectrum disorders, clinically significant mood disorders) AND/OR one or more of the following:
- Evidence of active relapse or active impairing symptoms (e.g., suicidal ideation, audio or visual hallucinations, paranoia, thought disturbance, severe impairment)
- Evidence of minimal supports or limited adherence to ongoing mental health care
- Failure to provide comprehensive aftercare plan that includes emergency plan for addressing future mental health relapse
- History of treatment refractory mental illness/recurrent relapse (multiple suicide attempts or inpatient psychiatric hospitalizations in the past 5 years)
- Within past 3 years: Inpatient psychiatric hospitalization
- Within past 5 years: Suicide attempt
- Declining to provide mental health records, a letter of support from mental health professionals, or consent for verbal consultation with mental health professionals when determined to be essential to evaluation.
- Cognitive impairment, if judged to have
- Limited capacity to make informed decision about procedure and inability to verbalize an understanding of the surgical procedure, risks and benefits.
- Inability to demonstrate an understanding of the permanency of lifestyle change required
- History of Anorexia or History of/Active Bulimia: If determined to be of low enough severity not to be a clear contraindication, minimum of 5 years abstinence from bulimia, current moderate to severe binge eating or night eating syndrome
- Active or History of Substance Abuse with less than 5 years of abstinence
- Current use of anti-tricyclic anti-depressants or steroids, psychiatric medications associated with weight gain.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Intervention
There will be 10 pilot patients (See Statistical Analysis below for sample size calculations) for a total of 59 participants.
Participants will be followed with study outcomes assessed for a period of 12 months.
The duration of the study will be approximately three years.
|
bariatric embolization will be performed using tiny (100-200 μm), radiopaque (visible on X-ray) beads (referred to as BTG-001933) in order to suppress the body's signals for feeling hungry, which we predict will lead to weight loss.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Body Weight as Assessed by BMI (kg/m^2)
Time Frame: 12 months
|
Efficacy of Bariatric Embolization procedure assessed by change in body weight as assessed by BMI.
|
12 months
|
|
Change in Body Weight (Pounds)
Time Frame: 12 months
|
Efficacy of Bariatric Embolization procedure assessed by change in body weight (pounds)
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Clifford Weiss, M.D., Johns Hopkins University
Publications and helpful links
General Publications
- Hu Z, Cha SH, van Haasteren G, Wang J, Lane MD. Effect of centrally administered C75, a fatty acid synthase inhibitor, on ghrelin secretion and its downstream effects. Proc Natl Acad Sci U S A. 2005 Mar 15;102(11):3972-7. doi: 10.1073/pnas.0500619102. Epub 2005 Feb 23.
- Loftus TM, Jaworsky DE, Frehywot GL, Townsend CA, Ronnett GV, Lane MD, Kuhajda FP. Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. Science. 2000 Jun 30;288(5475):2379-81. doi: 10.1126/science.288.5475.2379.
- Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes. 2001 Aug;50(8):1714-9. doi: 10.2337/diabetes.50.8.1714.
- Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999 Dec 9;402(6762):656-60. doi: 10.1038/45230.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IRB00143169
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.